Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TZP-101 (Ulimorelin) for Postoperative Ileus in Major Open Abdominal Surgery
NCT00617552Phase 2Completed
- Sponsor
- Tranzyme Pharma
- Start
- Jul 2007
- Primary completion
- Jul 2008
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of ulimorelin in postoperative ileus (POI) (8 arms), sponsored by Tranzyme Pharma. Primary endpoint: Time to recovery of gastrointestinal function up to 14 days. Started Jul 2007; status: completed.
02
Drugs
ulimorelin
03
Conditions
postoperative ileus (POI)
Beyond the preview
Go deeper on NCT00617552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00617552.